These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240 [TBL] [Abstract][Full Text] [Related]
7. Current Treatment of Drug-Resistant Tuberculosis in Children. Schaaf HS; Hughes J Indian J Pediatr; 2024 Aug; 91(8):806-816. PubMed ID: 37995068 [TBL] [Abstract][Full Text] [Related]
8. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492 [TBL] [Abstract][Full Text] [Related]
9. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907 [TBL] [Abstract][Full Text] [Related]
10. Management of multidrug resistant tuberculosis. Daley CL; Caminero JA Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005 [TBL] [Abstract][Full Text] [Related]
11. Multi-drug resistant tuberculosis burden and risk factors: an update. Marahatta SB Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520 [TBL] [Abstract][Full Text] [Related]
12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
13. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832 [TBL] [Abstract][Full Text] [Related]
14. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Seaworth BJ; Griffith DE Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737 [TBL] [Abstract][Full Text] [Related]
15. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
16. Standardised shorter regimens Abidi S; Achar J; Assao Neino MM; Bang D; Benedetti A; Brode S; Campbell JR; Casas EC; Conradie F; Dravniece G; du Cros P; Falzon D; Jaramillo E; Kuaban C; Lan Z; Lange C; Li PZ; Makhmudova M; Maug AKJ; Menzies D; Migliori GB; Miller A; Myrzaliev B; Ndjeka N; Noeske J; Parpieva N; Piubello A; Schwoebel V; Sikhondze W; Singla R; Souleymane MB; Trébucq A; Van Deun A; Viney K; Weyer K; Zhang BJ; Ahmad Khan F Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31862767 [TBL] [Abstract][Full Text] [Related]
17. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049 [TBL] [Abstract][Full Text] [Related]
18. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries. Chiang CY; Lin CJ Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663 [TBL] [Abstract][Full Text] [Related]
19. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. Mesic A; Khan WH; Lenglet A; Lynen L; Ishaq S; Phyu EHH; Mar HT; Oraegbu A; Seddiq MK; Amirzada HK; Fernhout J; Kamau C; Ariti C; Gomez D; Decroo T PLoS One; 2020; 15(8):e0237787. PubMed ID: 32822375 [TBL] [Abstract][Full Text] [Related]
20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]